A French drugs company has increased it stock to give it a 14 week buffer in the case of a hard Brexit.
The company, Sanofi, is increasing various product lines, including insulin. The concern is that if the UK can’t reach a deal with the UK there could be transportation issues by land and air.
Hugo Fry, managing director, Sanofi UK said: “The uncertainty in the Brexit negotiations means that Sanofi has been planning for a ‘no deal’ scenario.”
He continued: “Patient safety is our main priority and we have made arrangements for additional warehouse capacity in order to stockpile our products, where global supply allows, in the UK and increase UK-based resource to prepare for any changes to customs or regulatory processes.”
Mr Fry said the preparations mean that “Sanofi will hold 14 weeks stock in the UK as from April 2019, which is an increase of our current in country holding of approximately 10 weeks stock and is based on our own internal assumptions of potential delays around a ‘no deal’ scenario”.
Last month, AstraZeneca said it was increasing drug stockpiles by about 20%in preparation for a no-deal Brexit.
Since you’re here …
We do not charge or put articles behind a paywall. If you can, please show your appreciation for our free content by donating whatever you think is fair to help keep TLE growing.
Every penny we collect from donations supports vital investigative and independent journalism. You can also help us grow by inviting your friends to follow us on social media.